

Orient Europharma subsidiary recognized by government as biotech and new pharmaceutical company

Taipei, Taiwan, Sept. 15, 2009 – Orient Pharma Co. Ltd., a subsidiary of Orient Europharma Co. Ltd. (OE, Taiwan OTC: 4120), today announced it has been recognized by Taiwan’s Industrial Development Bureau (IDB) under the Ministry of Economic Affairs (MOEA) as a “biotech and new pharmaceutical company” in accordance with the Biotech and New Pharmaceutical Development Act.

The biotech industry has become Taiwan’s next “trillion-dollar industry.” Designed to offer incentives to pharmaceutical and biotech companies, the Biotech and New Pharmaceutical Development Act that went into force February 2008 sets forth strict rules for qualification. All companies applying for recognition as a biotech and new pharmaceutical company must meet the MOEA’s criteria on personnel, technology, and capital.

Orient Pharma’s recognition as a biotech and new pharmaceutical company therefore proves that its personnel, technology and capital are up to standards. The company is committed to continuing its efforts on the research and development (R&D) and manufacturing of pharmaceuticals.

Under the act, Orient Pharma may offset 35 percent of its spending on R&D and personnel training from its enterprise income tax within five years of the date on which such tax is due. The act also stipulates that institutional investors that hold shares in biotech and new pharmaceutical companies continuously for at least three years may offset 20 percent of the original cost of purchasing the shares from their enterprise income tax over a period of five years. This act grants Orient Pharma advantages in new drug research and development, including new ingredients, new compounds, new applications and others.

The act will benefit two drugs currently undergoing R&D at Orient Pharma, OP014, a compound formulation for the treatment of sialorrhoea or excessive drooling and OP010, a sustained-release sleeping tablet.

In addition to treating patients with Parkinson's disease, the OP014 compound formulation can also be used to treat those with ailments marked by sialorrhoea such as cerebral palsy, esophageal cancer, survivors of stroke, amyotrophic lateral sclerosis and Duchenne muscular dystrophy. It is estimated that the global market for this drug amounts to US\$1 billion. Orient Pharma has obtained approval from Taiwan’s Department of Health to conduct clinical trials for the drug in April 2009. Phase I

clinical trials were completed in August 2009 and phase II clinical trials are scheduled to begin next year.

Using an innovative dual-release formulation developed by Orient Pharma, the OP010 sustained-release sleeping tablet combines a rapid-acting layer and a slow release layer that allow safe and fast results without the side effect of drug residue. The development of the Duo Release technology was selected to receive endowment from The Small Business Innovation Research (SBIR) program of the Ministry of Economic Affairs' Department of Industrial Technology for its potential in future applications.

Orient Pharma is committed to conduct R&D and perform clinical trials of new drugs that, following regulatory approvals, can be produced in commercial quantities at its new plant scheduled for completion in 2010.

About Orient Pharma Co. Ltd.

Orient Pharma was established in 2008 with an initial investment of NT\$800 million and is located in the Central Taiwan Science Park in Yunlin. The new plant will be launched in 2010.

Orient Pharma is designed to comply with the international standards of the U.S. FDA's cGMP and the European PIC/S. Current technologies include multi-stage liquid fill and transdermal technologies. Products under development include a next-generation drug to lower cholesterol, new compound formulations, as well as others indicated for cardiovascular diseases, Alzheimer's disease, and neurodegenerative disorders.